Core Insights - Microbial protein is emerging as a new, nutritious, and efficient alternative protein source, driven by technological advancements and increasing demand for high-quality protein in China [1][2] - The market for microbial protein is projected to reach approximately 60 billion yuan by 2035, with growth catalyzed by technological progress and potential policy support [2] - Key players in the industry include innovative startups and traditional leaders, each leveraging their strengths in technology and capital to capture market opportunities [3][4] Industry Overview - The demand for high-quality protein in China is rising, while supply is constrained by reliance on imported plant proteins and limited animal protein production [1] - Microbial protein, as a subset of alternative proteins, offers superior nutritional profiles and production efficiency, with ongoing commercialization efforts [1][2] - The industry is currently in the introduction and validation phase, with significant advancements in commercial viability since 2020 [2] Technological Pathways - Two main technological pathways for microbial protein production are identified: biomass fermentation and precision fermentation, with the latter being more complex but offering higher value-added products [2] - The commercial maturity of biomass fermentation is higher, particularly in meat and dairy products, while precision fermentation is still developing [2] Competitive Landscape - Innovative startups are leading in technological advancements, while traditional companies are leveraging their financial and operational synergies to enter the market [3][4] - Major players like Budweiser and Angel Yeast are building large-scale production capacities, significantly outpacing smaller startups [3] Future Outlook - Technology is the core competitive factor across all stages of microbial protein development, influencing product development, regulatory approval, and cost efficiency [4] - The ability to scale production and reduce costs will favor early entrants in the market, enhancing their competitive position [4]
华创证券:微生物蛋白商业化加速开探 建议关注安琪酵母(600298.SH)、富祥药业(300497.SZ)